168 related articles for article (PubMed ID: 38542016)
1. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management.
Borgia P; Piccolo G; Santangelo A; Chelleri C; Viglizzo G; Occella C; Minetti C; Striano P; Diana MC
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542016
[No Abstract] [Full Text] [Related]
2. Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change.
Baldo F; Magnolato A; Barbi E; Bruno I
BMC Pediatr; 2021 Feb; 21(1):67. PubMed ID: 33549085
[TBL] [Abstract][Full Text] [Related]
3. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
[TBL] [Abstract][Full Text] [Related]
4. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
[TBL] [Abstract][Full Text] [Related]
5. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas.
Sharawat IK; Panda PK; Sihag RK; Panda P; Dawman L
J Neurosurg Sci; 2022 Dec; 66(6):501-510. PubMed ID: 35301838
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
[TBL] [Abstract][Full Text] [Related]
9. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK; Johnson M; Thornburg L; Halford Z
Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
[TBL] [Abstract][Full Text] [Related]
11. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
[TBL] [Abstract][Full Text] [Related]
12. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
Balagula Y; Barth Huston K; Busam KJ; Lacouture ME; Chapman PB; Myskowski PL
Invest New Drugs; 2011 Oct; 29(5):1114-21. PubMed ID: 20978926
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
[TBL] [Abstract][Full Text] [Related]
14. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.
Jackson S; Baker EH; Gross AM; Whitcomb P; Baldwin A; Derdak J; Tibery C; Desanto J; Carbonell A; Yohay K; O'Sullivan G; Chen AP; Widemann BC; Dombi E
Neurooncol Adv; 2020; 2(1):vdaa095. PubMed ID: 32939452
[TBL] [Abstract][Full Text] [Related]
15. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.
Baldo F; Grasso AG; Cortellazzo Wiel L; Maestro A; Trojniak MP; Murru FM; Basso L; Magnolato A; Bruno I; Barbi E
Paediatr Drugs; 2020 Aug; 22(4):417-423. PubMed ID: 32533336
[TBL] [Abstract][Full Text] [Related]
16. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
18. FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.
Casey D; Demko S; Sinha A; Mishra-Kalyani PS; Shen YL; Khasar S; Goheer MA; Helms WS; Pan L; Xu Y; Fan J; Leong R; Liu J; Yang Y; Windsor K; Ou M; Stephens O; Oh B; Reaman GH; Nair A; Shord SS; Bhatnagar V; Daniels SR; Sickafuse S; Goldberg KB; Theoret MR; Pazdur R; Singh H
Clin Cancer Res; 2021 Aug; 27(15):4142-4146. PubMed ID: 33712511
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
Vaassen P; Dürr NR; Rosenbaum T
Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas.
Viskochil D; Wysocki M; Learoyd M; Sun P; So K; Evans A; Lai F; Hernàndez HS
Neurooncol Adv; 2024; 6(1):vdae036. PubMed ID: 38721358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
